Literature DB >> 8985381

Characterization of an abundant, unique 1.7-kilobase bovine herpesvirus 4 (BHV-4) late RNA and mapping of a BHV-4 IE2 transactivator-binding site in its promoter-regulatory region.

R Bermudez-Cruz1, L Zhang, V L van Santen.   

Abstract

We characterized an abundant late 1.7-kb cytoplasmic polyadenylated RNA (L1.7 RNA) transcribed from the bovine herpesvirus 4 (BHV-4) HindIII W fragment, in a region of the genome not conserved with Epstein-Barr virus and herpesvirus saimiri. L1.7 RNA contains only extremely short (<100 nucleotides) open reading frames followed by two repeat arrays. The first repeat array contains 11 copies of a 23-bp unit, TGGCACTA GTAGCATTTAACCCC. The second and third copies are each interrupted by 15- to 17-bp sequences that are identical to each other for the first 15 bp. In addition, the second and third copies of the repeat unit each contain two copies of nucleotides 5 to 9 (ACTAG) of the repeat unit, one at each end of the interruption. The second repeat array contains 12 copies of a 25-bp sequence, GCTGTGTATTATTGAGTATTTTTTA. The promoter-regulatory region of L1.7 was activated by the BHV-4 immediate-early gene 2 product (IE2), a homolog of the Epstein-Barr virus R transactivator, in cotransfection assays. We mapped an IE2 recognition site within a 167-bp fragment approximately 10 bp 5' to the start of L1.7 RNA transcription, using cotransfection assays and gel retardation assays. Using gel retardation assays, we mapped an IE2-binding site within this fragment to a 31-bp region from 56 to 86 bp 5' to the start of L1.7 RNA transcription. This IE2-binding site was able to transfer IE2 responsiveness to a heterologous promoter. However, IE2 responsiveness was affected by both position and orientation. Alignment of the L1.7 IE2-binding site sequence with sequences of two other BHV-4 IE2-binding sites resulted in a provisional IE2-binding site consensus sequence different from the Epstein-Barr virus R transactivator-binding site.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8985381      PMCID: PMC191082     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators.

Authors:  S Kenney; E Holley-Guthrie; E C Mar; M Smith
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) early protein EB2 is a posttranscriptional activator expressed under the control of EBV transcription factors EB1 and R.

Authors:  M Buisson; E Manet; M C Trescol-Biemont; H Gruffat; B Durand; A Sergeant
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

3.  The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R.

Authors:  A Chevallier-Greco; H Gruffat; E Manet; A Calender; A Sergeant
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  The Epstein-Barr virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities.

Authors:  P Chavrier; H Gruffat; A Chevallier-Greco; M Buisson; A Sergeant
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  A single regulatory region modulates both cis activation and trans activation of the herpes simplex virus VP5 promoter in transient-expression assays in vivo.

Authors:  E D Blair; E K Wagner
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

6.  A simple phase-extraction assay for chloramphenicol acyltransferase activity.

Authors:  B Seed; J Y Sheen
Journal:  Gene       Date:  1988-07-30       Impact factor: 3.688

Review 7.  Splicing of messenger RNA precursors.

Authors:  R A Padgett; P J Grabowski; M M Konarska; S Seiler; P A Sharp
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

8.  Deviations from expected frequencies of CpG dinucleotides in herpesvirus DNAs may be diagnostic of differences in the states of their latent genomes.

Authors:  R W Honess; U A Gompels; B G Barrell; M Craxton; K R Cameron; R Staden; Y N Chang; G S Hayward
Journal:  J Gen Virol       Date:  1989-04       Impact factor: 3.891

9.  An enhancer within the divergent promoter of Epstein-Barr virus responds synergistically to the R and Z transactivators.

Authors:  M A Cox; J Leahy; J M Hardwick
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

10.  A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen.

Authors:  J M Hardwick; P M Lieberman; S D Hayward
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

View more
  5 in total

1.  Genome sequence of bovine herpesvirus 4, a bovine Rhadinovirus, and identification of an origin of DNA replication.

Authors:  W Zimmermann; H Broll; B Ehlers; H J Buhk; A Rosenthal; M Goltz
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  The Expression and Nuclear Retention Element of Polyadenylated Nuclear RNA Is Not Required for Productive Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.

Authors:  Isaura Vanessa Gutierrez; Jacob Dayton; Shannon Harger; Cyprian C Rossetto
Journal:  J Virol       Date:  2021-06-10       Impact factor: 5.103

3.  Conservation of a triple-helix-forming RNA stability element in noncoding and genomic RNAs of diverse viruses.

Authors:  Kazimierz T Tycowski; Mei-Di Shu; Sumit Borah; Mary Shi; Joan A Steitz
Journal:  Cell Rep       Date:  2012-07-05       Impact factor: 9.423

4.  Two herpesviral noncoding PAN RNAs are functionally homologous but do not associate with common chromatin loci.

Authors:  Johanna B Withers; Eric S Li; Tenaya K Vallery; Therese A Yario; Joan A Steitz
Journal:  PLoS Pathog       Date:  2018-11-01       Impact factor: 6.823

Review 5.  PAN RNA: transcriptional exhaust from a viral engine.

Authors:  Mel Campbell; Yoshihiro Izumiya
Journal:  J Biomed Sci       Date:  2020-03-07       Impact factor: 8.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.